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Abstract
Cardiac disease modeling is crucial to improve our understanding of the mecha-
nism of various cardiac diseases and to discover new therapeutic approaches. Several 
modeling methods such as animal and computer simulations have been used to elu-
cidate the cardiac diseases’ mechanism and drug responses. However, each modeling 
technique has its own particular advantages and limitations. Human-based models 
would be particularly useful to investigate human cardiac diseases because humans 
and animals have differing cardiac physiologies and drug tolerability. In addition, 
the phenotype of cardiac diseases and response to therapeutic intervention differ not 
only between mutations but also among patients. Therefore, such diseases strongly 
demand the individualized/personalized strategies. Human-induced pluripotent 
stem cell-derived cardiomyocytes (hiPSC-CMs) offer the striking feature of retain-
ing the same genetic information as donor, which guide us to investigate diseases 
and predict response to drug treatment individually. This feature of hiPSC-CMs is 
superior to the conventional in vitro modeling of cardiac diseases. Thus far, hiPSC-
CMs have been successfully recapitulated many monogenic and also complex genetic 
cardiac diseases. hiPSC-CMs could be differentiated into different types of cardio-
myocytes and non-cardiomyocyte cells, which empower us to understand cardiac 
chamber-specific arrhythmias such as atrial fibrillation and ventricular tachycardia.
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1. The importance of hiPSC-CMs
Cardiovascular diseases (CVDs) are the major causes of premature death and 
chronic disability worldwide [1]. Among CVD-related deaths, the occurrence of 
inherited lethal arrhythmias is the main reason for sudden cardiac death (SCD) in 
cardiac patients especially at young age [2]. Although many risk factors associated 
with SCD have been identified and understanding of pathogenesis of many cardiac 
diseases is progressing, the considerable number of cardiac patients still suffers SCD 
without warning, and we are still far from disease-specific treatment. Heterogeneous 
and multifactorial natures of genetic cardiac diseases are reasons for these complica-
tions. Furthermore, founder mutations causing cardiac disease have been reported in 
Finland [3], the Netherlands [4], and South Africa [5]. Not only disease phenotypes 
vary among different mutations, but also these vary among individuals carrying the 
same mutation. For example, long QT syndrome (LQTS) patients demonstrate a wide 
range of clinical phenotypes even among family members with the identical muta-
tion [6]. Despite carrying the same gene variant resulting in cardiac disease, patients 
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often demonstrate the wide spectrum of clinical outcomes ranging from the absence 
of distinct electrocardiogram (ECG) abnormalities and being lifelong asymptomatic 
to clear abnormalities in ECG (e.g., prolonged QT interval and arrhythmias) and pre-
mature SCD. In addition, SCD could also be the first manifestation of cardiac disease. 
These suggest that the type of genetic mutation cannot always be the sole factor that 
dictates the prognosis of disease and clinical phenotype in all individuals who carry 
it [7]. Thus, genetic cardiac diseases exhibit the incomplete penetrance and differ 
among genetic cardiac diseases. For example, Brugada syndrome (BrS) has a penetra-
tion range from 12.5 to 50%; mean penetrance of LQTS is ~40%, while overall pen-
etrance of catecholaminergic polymorphic ventricular tachycardia (CPVT) is 78% 
[7]. Another convoluting factor that hinders the genotype-phenotype correlation is 
variable expressivity within one phenotype because some mutation carriers display 
all the phenotypic symptoms, whereas some only display part of mutation-specific 
phenotypes [8]. The clinical heterogeneity of genetic cardiac diseases suggests that 
ultimate disease severity (i.e., penetrance and expressivity) does not solely depend 
on one particular gene causing cardiac disease, but instead results from the combina-
tion of many modifying factors such as age, gender, and environmental and lifestyle 
factors, which either exacerbate or protect against disease [9]. In addition, patients 
carrying more than one disease-causing mutations (i.e., not polymorphisms) either 
in the same gene or different genes yield to more severe clinical disease including 
earlier onset of disease, early heart failure, and premature SCD [10]. Besides these, 
some of the cardiac diseases overlap their phenotypes with other cardiac diseases 
(Figure 1). For example, mutations in cardiac sodium (Na+) channel gene, SCN5A, 
are associated with type 3 long QT (LQT3), BrS, cardiac conduction diseases, and 
sinus node dysfunction [11]. These incomplete penetrance, variable expressivity, and 
phenotypic overlap impede the complete understanding of diseases’ mechanism as 
well as disease-specific treatment. Furthermore, the treatment therapies are mainly 
targeted for symptomatic patients to prevent and counteract the symptoms, but 
treatments in asymptomatic individuals are still of concern with variable opinions. 
Nevertheless, pharmacological therapies have been resulted in poor outcomes in the 
Figure 1. 
Heterogeneity of genetic cardiac diseases. (A) Overlapping genes causing channelopathies [27]. Brugada 
syndrome (BrS), long QT syndrome (LQTS), short QT syndrome (SQTS), catecholaminergic polymorphic 
ventricular tachycardia (CPVT) (ref). (B) Overlapping genes causing cardiomyopathies [72]. Arrhythmogenic 
right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 
(HCM), restrictive cardiomyopathy (RCM), left ventricular non-compaction cardiomyopathy (LVNC).
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cardiac diseases [12]. So far, implantable cardioverter-defibrillator (ICD) is the only 
proven therapy for preventing detrimental consequences in cardiac patients with high 
risk of SCD [13]. However, ICD implantation is associated with its own complications 
and lower quality of life [14]. There are large groups of asymptomatic cardiac patients 
who do not have risk factors, which shift them into high-risk category as candidate 
for ICD implantation, but suffer SCD. Thus, the management for asymptomatic 
patients carrying pathogenic variant is the most challenging since SCD could be 
the first manifestation of disease [15, 16]. The clinical management of most cardiac 
diseases is suboptimal due to lack of comprehensive knowledge of mutations and 
possible mechanism involved. Thus, the mechanism of how mutation leads to modify 
the normal cardiac physiology and engender lethal arrhythmias should be deciphered 
so that the promising prevention and treatment could be established.
The prior cardiovascular research and drug screening have mostly been performed 
in animal models through knock-in/knock-out approaches. Although animal models 
have provided some fundamental information and led to many discoveries in genetic 
cardiac disease, physiological and pharmacological results cannot directly extrapolate 
from animals to humans because of some fundamental differences that exist between 
animal and human cardiac physiology [17]. For example, the resting heart rate of 
human is 75 bpm, while that of rat is 300 bpm, and the animal (mice and rats) can 
tolerate 6–400-fold higher concentration of some drugs compared to human [18]. 
The animal models become even worse when studying human cardiomyopathies due 
to mutations in contractile proteins, which are not highly expressed in mouse or rat. 
Therefore, it is more complicated to extrapolate physiological and pharmacologi-
cal results from animal to human [17, 18]. Furthermore, most of cardiovascular 
drug screening and toxicology studies were performed in non-cardiac cell lines or 
animals, which do not accurately represent human CMs. Thus, considerable amount 
of cardiovascular drugs were withdrawn from market due to off-target effects [19]. 
Therefore, human tissues are required to study the human cardiac diseases and drug 
Figure 2. 
hiPSC-CM-based modeling of human genetic cardiac diseases. Human-induced pluripotent stem cells (hiPSCs) 
can be differentiated into hiPSC-derived cardiomyocytes (hiPSC-CMs). There are at least three subtypes 
of hiPSC-CMs, namely, ventricular-like, atrial-like, and nodal-like hiPSC-CMs. hiPSC-CMs derived 
from cardiac patients carrying genetic mutation recapitulate calcium and electrical abnormalities (early 
afterdepolarization (EAD) and delayed afterdepolarization (DAD)). Newly emerging gene editing techniques 
were able to mitigate these abnormalities in hiPSC-CMs.
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testing. However, the human sample exhibits some of the major challenges: there is 
limited supply of human cardiac biopsies, and it involves complex procedures and 
ethical issues. In addition, these cardiac biopsies are typically obtained from the end 
stage of cardiac diseases; hence it is not possible to understand the mechanism of 
cardiac diseases [20, 21]. These obstacles are mostly overcome by the groundbreaking 
discovery of reprogramming adult somatic cells into induced pluripotent stem cells 
(iPSCs) [22, 23] which can be differentiated into cardiomyocytes (CMs) (hiPSC-
CMs) [24–26]. The main advantages of hiPSC-CMs are iPSCs can be generated at any 
period of a patient’s life, they have unlimited supply, and these retain the same genetic 
information as the donor, i.e., hiPSC-CMs are patient specific (Figure 2). These are 
superior features of hiPSC-CMs to the conventional in vitro modeling of cardiac 
diseases. In addition, hiPSC-CMs can be cultured for several months, which enable us 
to study acute and chronic effect of mutation and drugs on CMs. Thus, hiPSC-CMs 
not only provide the platform to investigate the mutation-specific mechanism but also 
assist to anticipate drug response on an individual basis and guide us to personalized 
medicine in future.
2. Channelopathy phenotypes in hiPSC-CMs
Channelopathy cardiac diseases are caused by mutations in cardiac ion channels 
located in the cellular membrane or organelles. Mutations in ion channels result 
in misbalance of fine-tuning ion exchange during excitation-contraction coupling 
(ECC), which could lead to cardiac arrhythmias and SCD in the worst case. The 
main cardiac channelopathies are CPVT, LQTS, BrS, and short QT syndromes 
(SQTS) [27]. These cardiac channelopathies have been extensively studied using 
hiPSC-CMs and described below.
2.1 Catecholaminergic polymorphic ventricular tachycardia (CPVT)
CPVT is an inherited cardiac disease with the prevalence of about 
1:5000/10,000. This disease is characterized by premature ventricular contraction 
and/or polymorphic ventricular tachycardia (VT) induced by adrenergic stimula-
tion in response to emotional stress or physical exercise in structurally normal 
heart. Over 150 mutations in ryanodine receptor type 2 (RYR2 gene) are responsible 
for ~ 55% of CPVT type 1 cases (CPVT1), and mutation in calsequestrin 2 (CASQ2 
gene) CPVT accounts for 3–5% CPVT type 2 (CPVT2) cases [28, 29]. In addi-
tion, mutations in calmodulin (CALM1) genes and in triadin (TRDN) have been 
reported causing CPVT. RYR2, CASQ2, CALM1, and TRDN are involved in ECC, 
and mutation in any of these genes results in elevated intracellular Ca2+, which 
leads to abnormal Ca2+ handling and arrhythmias [28, 29]. In consistency with 
clinical phenotype, many hiPSC-CM model had demonstrated the exacerbation 
of electrophysiological and Ca2+ handling abnormalities upon adrenergic stimula-
tion [26, 30–32]. Furthermore, Zhang and colleagues had modeled hiPSC-CMs 
harboring CPVT1-associated F2483I mutation in RYR2 gene and demonstrated that 
CPVT1 hiPSC-CMs had longer and wandering Ca2+ sparks and smaller sarcoplasmic 
reticulum Ca2+ content [32]. Later on, the same group corrected this mutation using 
clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) 
gene editing technique and showed that this mutation is causative rather than asso-
ciative to the disease [33]. hiPSC-CM model for CPVT has also been used in study-
ing the efficacy of various drugs. Previously we had directly compared the clinical 
results from CPVT1 patients with dantrolene medication, and the clinical response 
of dantrolene was similar as in hiPSC-CMs from the same patients; dantrolene 
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abolished or markedly reduced arrhythmias in patients and their hiPSC-CMs with 
certain mutation in RYR2, while it did not have any clinical effect with hiPSC-
CMs or with other RYR2 mutations [31]. Furthermore, an antiarrhythmic drug, 
flecainide, used to treat CPVT1 patients [34] was able to reduce the Ca2+ irregulari-
ties under adrenergic stimulation in CPVT1 hiPSC-CMs [30, 35]. CPVT2 patients 
harboring homozygous CASQ2-G112 + 5X mutation in CASQ2 gene showed the 
rapid polymorphic VT under exercise stress test [36]. Adult rat ventricular myocytes 
were studied to understand the effect of CASQ2 mutation in ECC, demonstrating 
that mutated CMs exhibited spontaneous extrasystolic Ca2+ elevations and delayed 
afterdepolarization (DADs) upon adrenergic stimulation [36]. Later, hiPSC-CM 
model harboring CASQ2-G112 + 5X mutation emulated these phenotypic features 
of disease, and AAV9-based gene delivery effectively prevents the development of 
adrenergic-induced DADs and triggered arrhythmias in CPVT2 hiPSC-CMs [37].
2.2 LQT type 1 (LQT1)
LQT type 1 (LQT1) is caused by loss-of-function mutation in KCNQ1 gene encod-
ing α subunit of potassium (K+) channel mediating slow delayed rectifier K+ current 
(IKs). LQT1 is responsible for 30–35% of all LQTS cases [38]. LQT1 is characterized by 
prolongation of QT interval in ECG, which could lead to SCD due to VT, typically tor-
sades de pointes [39]. hiPSC-CMs derived from LQT1 patients faithfully recapitulated 
the clinical hallmark by showing prolonged action potential duration (APD) which is 
analogous to QT duration in ECG, and reduced IKs current densities are held respon-
sible for abnormal repolarization [40–42]. ML277, an IKs activator, increased the IKs 
amplitude by enhancing the activation of IKs, thus resulting in shortening of APD 
in LQT1 hiPSC-CMs [40]. In addition, adrenergic stimulation in LQT1 hiPSC-CMs 
induced the early afterdepolarization (EAD) [42], which is similar to arrhythmias 
triggered in LQT1 patients by exercise or emotional stress [39]. Clinically, β-blockers 
were effective in minimizing the risk of cardiac events in LQT1 patients [43]. Similar 
antiarrhythmic effect of β-blockers has been observed in LQT1 hiPSC-CMs [42]. 
Furthermore, hypokalemia is the electrolyte disturbance caused by lower K+ level in 
blood serum, which aggravates the QT prolongation and facilitates the development 
of hypokalemia-induced torsades de pointes in LQT1 patients [39, 44]. We success-
fully developed and mimicked these disease phenotypes in LQT1 hiPSC-CMs carrying 
G589D or IVS7-2A > G mutation in KCNQ1 gene. Additionally, lowering the extracel-
lular K+ concentration prolonged APDs and induced the formation of EADs in LQT1 
hiPSC-CMs [45]. Both G589D- and IVS7-2A > G-specific LQT1 hiPSC-CMs displayed 
longer APD and higher Ca2+ abnormalities in baseline; G589D hiPSC-CMs dem-
onstrated prolonged contraction, while IVS7-2A > G hiPSC-CMs showed impaired 
relaxation [46] observed in our video image-based software analysis [47].
2.3 LQT type 2 (LQT2)
LQT type 2 (LQT2) is an LQTS subtype, which is caused by loss-of-function 
mutations in KCNH2 gene also known as human ether-a-go-go-related gene (hERG) 
encoding K+ channel mediating rapid delayed rectifier K current (IKr). LQT2 is 
responsible for approximately 25–30% of all LQTS cases [38]. Similar to LQT1, LQT2 
patients also exhibit the prolongation of QT interval and torsades de pointes. As in 
LQT1 hiPSC-CM model, LQT2 hiPSC-CMs also recapitulated clinical phenotypes by 
displaying longer APD resulted from reduced IKr current densities and enhanced EAD 
following the adrenergic stimulation [48–50]. Our early study of LQT2 hiPSC-CMs car-
rying R176W mutation in KCNH2 gene demonstrated the reduced IKr current densities, 
prolonged repolarization, and increased arrhythmogenicity although the donor is an 
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asymptomatic carrier [50]. These results are in parallel with clinical findings that LQT2 
patients usually display symptoms when heart rate is slow. In addition, this report illus-
trated that electrophysiological abnormalities can be detected in hiPSC-CMs, although 
iPSCs are derived from asymptomatic carriers of KCNH2 mutations. The application of 
IKr blockers (E4031 and sotalol) further prolonged the APD resulting in EADs, whereas 
Ca2+ channel blocker (nifedipine), IK,ATP channel opener (pinacidil and nicorandil), 
and IKr channel enhancer (PD-118057) reduced the APD and thus mitigated the forma-
tion of EAD in LQT2 hiPSC-CMs [48, 49]. Several novel pharmacological strategies 
including ICA-105574 (potent IKr activator) [51], chaperone modulator N-[N-(N-acetyl-
L-leucyl)-L-leucyl]-L-norleucine (ALLN) [52], LUF7346 (hERG allosteric modulators) 
[53], as well as application of allele-specific RNA interference approach [54] have been 
attempts to rescue the LQT phenotype in LQT2 hiPSC-CMs. Correcting the mutation 
associated with LQT2 not only confirmed that mutation caused IKr reduction and APD 
prolongation but also suggested that trafficking defect as the pathological mechanism is 
responsible for the electrophysiological phenotype in LQT2 [51, 55].
2.4 LQT type 3 (LQT3)
LQT type 3 (LQT3) is caused by gain-of-function mutations in SCN5A encoding 
α subunit of cardiac Na+ channels [56]. The gain-of-function SCN5A mutation results 
in augmented late or persistent Na+ current (INaL), which leads to prolongation of QT 
interval in ECG and proarrhythmia. LQT3 is the third most common LQTS accounting 
for 5–10% of all LQTS cases [56]. LQT3 patients exhibit longer QT duration at slower 
heart rate, thus LQT3 patients are at higher risk for cardiac events during rest or sleep 
[57]. LQT3 patients harboring V1763 M mutation in SCN5A [58] R1644H mutation in 
SCN5A [59] or F1473C mutation in SCN5A and a polymorphism (K897 T) in KCNH2 
[60] had prolonged QT interval, and in vitro models using hiPSC-CMs derived from 
all those LQT3 patients demonstrated prolonged APD resulting in the larger INa,L and 
altered biophysical properties of Na+ channels [58–60]. Mexiletine, a Na+ channel 
inhibitor commonly used in LQT3 therapy, lowered the INa,L and thereby rescued the 
APD prolongation phenotype [58, 59] and suppressed the occurrence of EAD [59] and 
also corrected the altered Na+ channel inactivation [60]. Incorporating the biophysics 
of Na+ channel and pharmacological analysis illustrated that the improper functioning 
of Na+ channel was responsible for LQT3 phenotypes rather than KCNH2 polymor-
phism [60]. In addition to LQT3, mutation in SCN5A gene can cause BrS, and mixed 
phenotypes are often seen, which is also known as the “overlap syndrome.” Loss in 
function of Na+ channel is often seen in BrS. Liang and co-workers had generated hiP-
SCs from two BrS patients, one with double missense mutation (R620H and R811H) 
in SCN5A gene (BrS(p1)) and another with one-base pair deletion mutation in the 
SCN5A gene (BrS(p2)), and showed that BrS hiPSC-CMs derived from both patients 
had reduced Na+ current and increased triggered activity and abnormal Ca2+ handling 
[61]. These phenotypes were alleviated by correcting the mutation by CRISPR/Cas9 in 
hiPSCs derived from BrS (p2) [61]. Importantly, only BrS hiPSC-CMs harboring BrS-
associated SCN5A-1795insD mutation displayed reduced Na+ current and upstroke 
velocity, but not with three sets of hiPSC-CMs derived from BrS patients who tested 
negative for mutations in the known BrS-associated genes suggesting the Na+ channel 
dysfunction may not be prerequisite for BrS [62]. In another study, Na+ current and 
upstroke velocity were reduced, but not the voltage-dependent inactivation in BrS 
hiPSC-CMs carrying the mutations R1638X and W156X [63].
2.5 LQT type 7 (LQT7) or Andersen-Tawil syndrome (ATS)
LQT type 7 (LQT7) or Andersen-Tawil syndrome (ATS) is a rare inherited cardiac 
disease associated with mutation in KCNJ2 gene (ATS type 1) encoding inward 
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rectifying K+ channel (Kir2.1) and accounts for ~70% of all ATS cases. However, the 
genetic cause of the remaining 30% of ATS (ATS type 2) remains unknown. In ATS 
patients, QT interval prolongation is not common, but prominent U wave and QU 
interval in ECG could be hallmarks of ATS, and they experienced cardiac arrhythmias 
including non-sustained VT and torsade de pointes [64]. Kuroda and co-workers 
generated hiPSCs from ATS patients carrying R218W, R67W, and R218Q mutations in 
KCNJ2 gene and showed strong arrhythmic events and higher incidence of irregular 
Ca2+ handling in ATS hiPSC-CMs, but flecainide and KB-R7943 (a reverse-mode  
Na+/Ca2+ exchanger inhibitor) were able to suppress those events [65].
2.6 LQT type 8 (LQT8) or Timothy syndrome (TS)
2.6 LQT type 8 (LQT8) or Timothy syndrome (TS) is a very rare genetic cardiac 
disease which results from mutation in CACNA1C gene encoding Ca2+ channel 
(CaV1.2). LQT8 is the most severe type of LQTS, which is characterized by markedly 
prolonged QT interval, severe ventricular arrhythmia, and multiorgan dysfunction 
[66]. hiPSC-CMs derived from TS patients recapitulated the disease phenotypes, but 
roscovitine rescued those abnormalities such as altered Ca2+ channel inactivation, 
prolonged APD, higher incidences of arrhythmias, and abnormal Ca2+ handling [67].
2.7 Short QT (SQT)
SQT is a rare inherited cardiac disease characterized by QT internal shortening, 
which is in contrast to QT prolongation observed in LQTS. SQT is associated with 
mutations in genes associated with K+ channel or Ca2+ channels [68]. The preva-
lence of SQT is between 0.02–0.1% and 0.05% in adults and children, respectively 
[69]. Recently El-Battrawy and co-workers had generated hiPSCs from SQT type 
1 patients carrying a mutation (N588K) in KCNH2, and hiPSC-CMs mimicked the 
clinical phenotype of SQT by showing a shortened APD as a result of increased 
IKr current densities [70]. In addition, SQT hiPSC-CMs exhibited abnormal Ca
2+ 
transients and rhythmic activities, which are enhanced by carbachol, but quinidine 
alleviated those carbachol-induced arrhythmias and prolonged the APD [70].
3. Cardiomyopathy phenotypes in hiPSC-CMs
Cardiomyopathies are diseases of cardiac muscle and associated with structural 
and/or functional abnormalities. The most common genetic cardiomyopathies are 
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). These genetic 
cardiomyopathies have been also extensively studied using hiPSC-CMs [71, 72].
3.1 Hypertrophic cardiomyopathy (HCM)
HCM is one of the most common genetic cardiac diseases with an estimate preva-
lence of 1 in 500. HCM is characterized by unexplained symmetrical or asymmetrical 
left ventricular hypertrophy. Mutations in sarcomeric proteins account for ~60% of 
all HCM cases including mutation in β-myosin heavy chain (MYH7), cardiac myosin-
binding protein C (MYBPC3), cardiac troponin I (cTnI), cardiac troponin T (cTnT), 
and tropomyosin (TPM1) [73]. Hypertrophy of myocytes and disarray of sarcomere 
are the histological hallmarks of HCM seen in cardiac biopsies from HCM patients 
[74], and these histological phenotypes are also observed in hiPSC-CM model of HCM 
[25, 75–77]. In addition, HCM hiPSC-CMs also demonstrated other hallmarks of HCM 
such as nuclear translocation of nuclear factor of activated T cells (NFAT) [75–77], 
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elevation of β-myosin/α-myosin ratio, and calcineurin activation [75]. Furthermore, 
isolated CMs from HCM patients displayed the prolonged APDs, increased Ca2+ 
current densities, reduced transient outward K+ current densities, abnormal Ca2+ 
handling, and increased frequency of arrhythmias [21]. These electrophysiological 
and Ca2+ transient irregularity phenotypes have been faithfully recapitulated in HCM 
hiPSC-CMs [25, 75, 76, 78]. When HCM tissues carrying a mutation in MYBPC3 gene 
were compared with donor heart sample, no specific truncated MyBP-C peptides were 
detected, but the overall level of MyBP-C in myofibrils was significantly reduced [79]. 
Similar haploinsufficiency results were also shown in HCM hiPSC-CMs with muta-
tion in MYBPC3 gene [25, 80], and gene replacement in HCM hiPSC-CMs partially 
improves the haploinsufficiency and reduces cellular hypertrophy [80]. Similar to 
higher myofilament Ca2+ sensitivity observed in isolated cardiac biopsies from HCM 
with E99K mutation in cardiac actin [81], in vitro model of HCM hiPSC-CMs carrying 
E99K mutation in cardiac actin demonstrated significantly stronger contraction and 
increased arrhythmogenic events [82] Furthermore, a study in HCM mice harbor-
ing I79N mutation in cTnT resulted in increased cardiac contractility, altered Ca2+ 
transients, and remodeling of action potential [83]. These phenotypes were faithfully 
recapitulated by HCM hiPSC-CMs carrying the same I79N mutation in cTnT [84]. 
These hypercontractility and increased arrhythmogenicity phenotypes were reversed 
in HCM hiPSC-CMs when the E99K mutation in cardiac actin [82] and I79N mutation 
in cTnT [84] were corrected using CRISPR/Cas9 gene editing technique. Recently, we 
have shown that HCM hiPSC-CMs carrying TPM1-Asp175Asn mutation exhibited VT 
type of arrhythmias [78], and this observation is in line with earlier clinical observa-
tion of HCM patients with TPM1-Asp175Asn mutation being at increased risk of fatal 
arrhythmias [85]. Currently, there is no specific pharmacological therapy for HCM 
patients, and drugs are prescribed mainly based on symptoms and personal history. 
However, drug therapy has also resulted in poor outcomes in HCM patients [12]. We 
reported the similar poor antiarrhythmic efficiency of β-blocker in preventing lethal 
arrhythmias in HCM hiPSC-CMs [78]. In another HCM report, several environmental 
factors were investigated with hiPSC-CMs to study their effect on disease progression 
[77]. They found that endothelin (ET)-1 was able to induce HCM phenotypes such 
as cellular hypertrophy and myofibrillar disarray in hiPSC-CMs, which are inhibited 
by ET receptor type A blocker [77]. HCM patients exhibited defects in mitochondrial 
functions and ultrastructure and abnormal energy metabolism [74]. These structural 
and functional phenotypes were recapitulated in hiPSC-CMs carrying m.2336 T > C 
mutation in mitochondrial genome causing HCM [86]. They reported that HCM 
hiPSC-CMs expressed reduced levels of mitochondrial proteins, ATP/ADP ratio, and 
mitochondrial membrane potential [86].
3.2 Dilated cardiomyopathy (DCM)
DCM is a myocardial disease characterized by ventricular chamber enlargement 
and systolic dysfunction and progressive heart failure without significant change in 
ventricular wall thickness. Mutations in >30 genes encoding proteins of cytoskel-
eton, sarcomere, and nuclear lamina are found in 30–35% of DCM patients [87]. 
DCM patients with mutations in RBM20, encoding RNA binding motif protein 20 
(RBM20), have an early onset of disease phenotype [88]. Isolated CMs from DCM 
patients carrying mutation in RBM20 displayed elongated and thinner sarcomere 
structure [88], and such disorganized sarcomeric structure phenotypes were reca-
pitulated in DCM hiPSC-CMs carrying mutation in RBM20 [89, 90]. RBM20 is the 
main regulator of the heart-specific titin splicing, and N2BA isoform is predomi-
nantly expressed in CMs from DCM patient carrying mutation in the RBM20 gene 
[91]. In vitro model of RBM20 hiPSC-CMs successfully mirrored the altered titin 
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isoform expression (titin isoform switch) [89, 90]. Furthermore, RBM20 hiPSC-CMs 
showed delayed Ca2+ extrusion and reuptake and more Ca2+ being released during 
each ECC, which resulted into deficient muscle contraction, the hallmark of cardiac 
dysfunction of DCM patients [89, 90]. In addition, a three-dimensional engineered 
heart muscle generated from RBM20 hiPSC-CMs showed an impaired force of con-
traction, and passive stress was decreased in response to stepwise increase in strain, 
suggesting higher viscoelasticity caused by mutation in RBM20 [89]. Besides HCM, 
mutation in cTnT also caused DCM and resulted in shifts in Ca2+ sensitivity and force 
of contraction [92]. Sun and co-workers generated iPSCs from DCM patients carry-
ing R173W mutation in cTnT and reported that DCM hiPSC-CMs exhibited altered 
Ca2+ handling, decreased contractility, and abnormal sarcomeric α–actinin distribu-
tion [93]. DCM patients with lamin A/C (LMNA) mutations show a highly variable 
phenotype. Cardiac biopsies from DCM patients harboring LMNA mutations exhibit 
reduced LMNA in nuclei with nuclear membrane damage such as focal disruption 
and nuclear pore clustering [94]. Nonsense mutation (R225X) in exon 4 of the 
LMNA gene causing DCM was associated with accelerated nuclear senescence and 
apoptosis of DCM hiPSC-CMs under electrical stimulation [95]. In another in vitro 
modeling of DCM, harboring A285V mutation in desmin (DES) using hiPSC-CMs 
displayed the pathogenic phenotypes of DCM such as diffuse abnormal DES aggre-
gation, poor co-localization of DES with cTnT, and Z-disk streaming with accumula-
tion of granulofilamentous materials or pleomorphic dense structures adjacent to the 
Z-disk or between the myofibrils [96]. DCM patients harboring R14del mutation in 
phospholamban (PLN) result in ventricular dilation, contractile dysfunction, and 
episodic ventricular arrhythmias [97]. Similarly, hiPSC-CMs carrying R14del muta-
tion in PLN induced the Ca2+ handling abnormalities, irregular electrical activity, 
and abnormal intracellular distribution of PLN in DCM hiPSC-CMs [98]. These PLN 
R14del-associated disease phenotypes were mitigated upon correction of PLN R14del 
mutation by transcription activator-like effector nuclease (TALENs) gene editing 
technique [98]. Furthermore, genetic correction of PLN R14del mutation by TALENs 
improved the force development and restored the contractile function in three-
dimensional human engineered cardiac tissue derived from R14del-iPSCs [99].
3.3 Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ARVC is rare genetic cardiac disease with the prevalence ranging from 1:000 
to 1:5000 worldwide. The histopathological hallmark of ARVC is the substitution 
of the cardiac myocytes with fibro-fatty deposits, particularly within the free 
wall of the right ventricle. The consequent results from the disruption of normal 
myocardial architecture can lead to right ventricular dysfunction, life-threatening 
arrhythmias, and SCD [100]. ARVC is caused by mutations in genes encoding 
desmosomal proteins such as plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 
(PKP2), desmoglein-2 (DSG2), and desmocollin-2 (DSC2) [100]. Similar to immu-
nohistological results from the biopsy sample from ARVC patients [101], ARVC 
hiPSC-CMs harboring a plakophilin 2 (PKP2) gene mutation mimicked the reduced 
PKP2 immunosignal [102, 103]. In addition, clusters of lipid droplets accumulat-
ing within the cytoplasm were identified in ARVC-hiPSC-CMs associated with 
structural distortion of desmosomes [103]. Another study showed that induction of 
adult-like metabolic energetics from an embryonic/glycolytic state and abnormal 
peroxisome proliferator-activated receptor gamma (PPARγ) activation underlie the 
pathogenesis of ARVC [104]. It has been observed that male ARVC patients develop 
earlier and more severe phenotype than female ARVC patients [105]. To understand 
whether sex hormones in serum may contribute to the major arrhythmic cardiovas-
cular events in ARVC, Akdis and co-workers combined a clinical study and in vitro 
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hiPSC-CM model and showed that increased levels of testosterone accelerate ARVC 
pathologies, while premenopausal female estradiol levels slow down exaggerated 
apoptosis and lipid accumulation in ARVC hiPSC-CMs [106].
4. Limitations and future prospective
The reprogramming of somatic cells into pluripotent stems cells and subsequent 
differentiation into specific cell types is a newly emerging technique and is certainly 
not free from limitation.
One of the most questionable issues of hiPSC-CMs is their maturity. Despite 
expressing relevant ion channels [107] and structural genes [25, 26, 75, 76, 89, 108],  
hiPSC-CMs lack t-tubules and exhibit lower expression of Kir2.1 and weaker 
contractility; thus they do not fully resemble adult CMs. In order to improve the 
maturity of hiPSC-CMs and consequently upgrade the functionality of hiPSC-CMs, 
various techniques have been investigated in different groups. Three-dimensional 
construction of engineered heart tissue is a rapidly growing technique for structural 
and functional maturations of hiPSC-CMs [109], which resulted in higher Na+ 
current density and upstroke velocity [110], and enhances the metabolic maturation 
[111] comparable to adult CMs. Furthermore, Shadrin and co-workers introduced 
the “Cardiopatch” platform for three-dimensional culture and maturation of 
hiPSC-CMs; this platform produces robust electromechanical coupling, consistent 
H-zone and I bands, and evidence of t-tubules and M-bands [112].
Another issue of hiPSC-CMs is the purity of differentiated CMs. The CMs 
differentiated from hiPSCs yield in heterogeneous population of CMs. There are 
at least three subtypes of CMs such as ventricular, atrial, and nodal CMs; among 
them the majority (~70%) of CMs are ventricular-like, and only a minority of 
CMs are atrial-like (~20%) and nodal-like (~10%) [40, 58, 93, 107]. Although 
many molecular and functional characteristics are shared among these CMs 
subtypes, they also exhibit their own unique features. For example, ventricular 
CMs have prominent plateau phase (phase 2) in action potential profile, atrial 
CMs exclusively exhibit IKur channels, and nodal CMs lack strong upstroke veloc-
ity [113]. Most of the published methods of differentiation protocol yield in a 
lower amount of atrial-like and nodal-like CMs [40, 58, 93, 107], but sufficient 
numbers of subtype-specific CMs are needed to understand the subtype-related 
disease mechanism and development of specific therapeutic approaches. Atrial 
fibrillation (AF) is one of the most common cardiac arrhythmias; however, current 
antiarrhythmic drugs for treatment of AF are not atrial-specific and could cause 
unacceptable ventricular events [114]. Thus, sufficient supply of atrial CMs is 
crucial for investigating the AF cellular mechanism. hiPSCs have been differenti-
ated into high-purity atrial-specific CMs by using retinoic acid signaling at the 
mesoderm stage of development [115]. These patient-specific atrial CMs allow us 
to investigate in detail mechanisms of AF and to develop atrial-specific therapeutic 
drugs. Furthermore, sinoatrial node (SAN) dysfunction can manifest bradycardia 
and asystolic pauses, but its pathophysiology is not completely understood [116]. 
SAN pacemaker cells from hiPSCs would facilitate the study of the disease mecha-
nism and provide a cell source for developing a biological pacemaker. Protze and 
co-workers had reported the transgene-independent method for the generation 
of pacemaker cells (nodal-like CMs) from human pluripotent stem cells by stage-
specific manipulation of developmental signaling pathways [117]. Besides CMs, 
the heart also consists of many other cell types such as fibroblast, endothelial and 
vascular smooth muscle cells, and also extracellular matrix. Importantly, the origin 
of cardiac diseases may not always exclusively originate from CMs, but might 
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involve non-CMs. Thus, incorporating the fibroblasts [118], endothelial cells [119], 
and vascular smooth muscle cells [120] into CMs from the same hiPSCs could offer 
new insight of disease mechanism.
The establishment of appropriate control is another challenge in disease model-
ing using hiPSC-CMs. It is generally argued/suggested that when comparing the 
results between control and mutated hiPSC-CMs, both should have the same genetic 
background. This objective is achieved in somehow by using healthy family mem-
bers as control [58, 93]. However, only ~50% of genome is shared between siblings, 
and phenotypic difference could result from DNA variants in the rest of genome 
besides disease-associated mutation [121]. Mutated genes can be corrected with the 
help of newly growing gene editing technology such as TALENs [98] and CRISPR/
Cas9 [33, 51, 84], thus establishing the so-called isogenic lines. This isogenic line 
would be the most appropriate control for comparison as it differs only in the pres-
ence and absence of mutation. Therefore, advance genome engineering will not only 
provide more reliable control lines but also guide us to understand how mutation 
modifies the normal functioning of cells. However, for diseased CMs without known 
mutation, healthy family members or otherwise controls are still the best.
5. Conclusion
While animal models fail to recapitulate human cardiac disease phenotype 
properly, hiPSC-CMs have been successful in recapitulating crucial phenotypes of 
many genetic cardiac diseases in terms of morphology, contractility, Ca2+ handling, 
ion channel biophysics, cell signaling, and metabolism. Most strikingly, hiPSC-CMs 
provide the patient-specific platform to study the disease mechanism and drug 
response individually, which the traditional disease modeling technique would never 
offer. In addition, cardiac subtype-specific arrhythmias and drug screening could be 
performed with the help of unlimited supply of hiPSC-CMs; thus chamber-specific 
treatment modalities could be identified. Certainly, by improving the current weak-
nesses of hiPSC-CMs and incorporating with new gene editing techniques, complex 
cardiac disease mechanism could be deciphered, and novel effective treatment 
therapies could be identified to improve the life of cardiac patients.
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